SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Chardan Capital

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reissued by investment analysts at Chardan Capital in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $25.00 target price on the stock. Chardan Capital’s price target indicates a potential upside of 473.39% from the stock’s previous close.

Separately, HC Wainwright lowered their price target on SAB Biotherapeutics from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $4.36 on Tuesday. The business’s 50 day moving average is $4.98 and its two-hundred day moving average is $3.09. The company has a current ratio of 5.45, a quick ratio of 5.45 and a debt-to-equity ratio of 0.06. SAB Biotherapeutics has a 12-month low of $4.00 and a 12-month high of $14.50.

Hedge Funds Weigh In On SAB Biotherapeutics

Hedge funds have recently bought and sold shares of the business. Pathstone Family Office LLC acquired a new position in shares of SAB Biotherapeutics during the third quarter valued at approximately $319,000. Pathstone Holdings LLC acquired a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $348,000. State Street Corp raised its holdings in shares of SAB Biotherapeutics by 244.2% during the first quarter. State Street Corp now owns 42,341 shares of the company’s stock valued at $159,000 after acquiring an additional 30,041 shares during the last quarter. First Manhattan CO. LLC. acquired a new stake in shares of SAB Biotherapeutics in the first quarter valued at approximately $122,000. Finally, Millennium Management LLC acquired a new stake in shares of SAB Biotherapeutics in the second quarter valued at approximately $93,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.